世界の膣炎治療薬市場2023-2030:疾患種類別(抗真菌、抗菌、ホルモン)、製品別(OTC、処方)、地域別

◆英語タイトル:Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが発行した調査報告書(GRV23NVB097)◆商品コード:GRV23NVB097
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2023年10月10日
◆ページ数:75
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,360,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

膣炎治療薬市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の膣炎治療薬市場規模は、2023年から2030年にかけて年平均成長率8.3%を記録し、2030年までに60億米ドルに達する見込みです。女性の意識レベルを高めるための政府や非政府機関による支援的な取り組みが、膣炎治療薬の需要を促進しています。アルコール消費量の増加も、これらの薬剤の採用を促進すると推定されています。米国では、約530万人の女性が健康と一般的な幸福に関連するリスクにさらされています。

さらに、膣炎治療薬の研究開発活動の高まりは、市場の成長を加速させると予想されています。米国国立アレルギー感染症研究所(NIAID)が資金を提供した研究により、イースト菌の発生行動に関するさまざまな重要なデータが発見され、イースト菌感染症の新しい治療法が生まれる可能性があります。加えて、主要企業による新薬の投入が市場の成長を促進すると期待されています。例えば、2017年9月、Symbiomix Therapeutics社は、細菌性膣炎の治療薬Solosec(secnidazole)のFDA承認を取得しました。

膣炎治療薬市場レポートハイライト

- 抗菌薬セグメントは、幅広い製品群の利用可能性と細菌性膣炎の症例数の増加により、2022年の売上高シェア37.9%で膣炎治療薬市場をリードしました。

- ホルモンは、パイプライン製品の存在と製品採用の増加により、予測期間のCAGRが8.4%となり、有利な成長が見込まれます。

- 処方薬セグメントは、処方薬の高い有効性と安全性、および重症で再発を繰り返す膣炎に対する幅広い薬剤の利用可能性により、2022年に51.2%の最大収益シェアで市場を牽引しました。

- 市販薬セグメントは、軽度の膣炎治療に対するFDA承認の増加により、今後数年間はCAGR 8.7%で拡大する見込みです。

- 北米は、質の高い医療サービスの提供と膣炎患者の増加により、2022年の売上高で38.3%のシェアを占め、市場を席巻しました。

- アジア太平洋地域は、予測期間のCAGRが約9.5%で、最も速い成長を目撃すると推定されています。この成長は、政府の積極的な取り組みと可処分所得の増加、および大規模なターゲット人口の存在によるものです。

第1章. 調査方法・範囲
第2章. エグゼクティブサマリー
第3章. 膣炎治療薬の市場変数・傾向・範囲
第4章. 膣炎治療薬の世界市場:疾患種類別予測・傾向分析
第5章. 膣炎治療薬の世界市場:製品別予測・傾向分析
第6章. 膣炎治療薬の世界市場:地域別予測・傾向分析
第7章. 競争状況

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Disease Type
1.1.2. Product
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease Type outlook
2.2.2. Product outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Vaginitis Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Vaginitis Therapeutics Market Analysis Tools
3.4.1. Industry Analysis – Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Vaginitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Vaginitis Therapeutics Market: Disease Type Key Takeaways
4.2. Vaginitis Therapeutics Market: Disease Type Movement & Market Share Analysis, 2022 & 2030
4.3. Anti-fungal
4.3.1. Anti-fungal market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Anti-bacterial
4.4.1. Anti-bacterial market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Hormone
4.5.1. Hormone market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Vaginitis Therapeutics Market: Product Estimates & Trend Analysis
5.1. Vaginitis Therapeutics Market: Product Key Takeaways
5.2. Vaginitis Therapeutics Market: Product Movement & Market Share Analysis, 2022 & 2030
5.3. Over-the-counter
5.3.1. Over-the-counter market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Prescription
5.4.1. Prescription market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Vaginitis Therapeutics Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Vaginitis Therapeutics Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Symbiomix Therapeutics LLC.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Merck & Co., Inc.
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Pfizer Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Novartis AG
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Teva Pharmaceutical Industries Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Bayer AG
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Janssen Pharmaceuticals Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Lupin Pharmaceuticals Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Lumavita AG
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Mission Pharmacal Company
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 3 North America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 4 North America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 6 U.S. vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 7 Canada vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 8 Canada vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 9 Europe vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 10 Europe vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 11 Europe vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 12 Germany vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 13 Germany vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 14 UK vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 15 UK vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 16 France vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 17 France vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 18 Italy vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 19 Italy vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 20 Spain vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 21 Spain vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 22 Sweden vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 23 Sweden vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 24 Norway vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 25 Norway vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 26 Denmark vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 27 Denmark vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 28 Asia Pacific vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 30 Asia Pacific vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 31 China vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 32 China vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 33 Japan vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 34 Japan vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 35 India vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 36 India vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 37 Australia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 38 Australia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 39 Thailand vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 40 Thailand vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 41 South Korea vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 42 South Korea vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 43 Latin America vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 44 Latin America vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 45 Latin America vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 47 Brazil vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 48 Mexico vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 49 Mexico vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 50 Argentina vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 51 Argentina vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa vaginitis therapeutics market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 56 South Africa vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 59 UAE vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 60 UAE vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)
Table 61 Kuwait vaginitis therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 62 Kuwait vaginitis therapeutics market, by product, 2018 - 2030 (USD Million)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の膣炎治療薬市場2023-2030:疾患種類別(抗真菌、抗菌、ホルモン)、製品別(OTC、処方)、地域別(Vaginitis Therapeutics Market Size, Share & Trends Analysis Report By Disease Type (Anti-fungal, Anti-bacterial, Hormone), By Product (OTC, Prescription), By Region, And Segment Forecasts, 2023 - 2030)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆